A phase II study of recombinant human al
β
Carol M. Van Haelst-Pisani; Ronald L. Richardson; John Su; Jan C. Buckner; Richa
π
Article
π
1992
π
John Wiley and Sons
π
English
β 306 KB
π 2 views
To determine the efficacy of recombinant human leukocyte alpha-interferon (IFL-RA) in advanced hormone-refractory prostate cancer, the authors treated 40 patients with IFL-RA administered intramuscularly at a dose of 10 x 10' U/m2 three times weekly. Toxicity was substantial and necessitated at leas